Anti-Her-2/neu-IL-2 or heregulin-IL-2 fusions proteins redirect non-tumor specific CTL to the tumor site for tumor eradication

Cancer Immunology, Immunotherapy

Volumn 52, Issue 12, 2003, Pages 751-760

  Lustgarten, Joseph ^a  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

Author keywords

Fusion proteins; Her family receptors; Interleukin 2; T cells; Tumor immunotherapy

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CELL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FAS ANTIGEN; FAS LIGAND; GROWTH FACTOR; HEMAGGLUTININ INTERLEUKIN 2 FUSION PROTEIN; HEREGULIN INTERLEUKIN 2 FUSION PROTEIN; HYBRID PROTEIN; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN; NEU ANTIBODY INTERLEUKIN 2 FUSION PROTEIN; NEU DIFFERENTIATION FACTOR; PROTEIN HER3; PROTEIN HER4; RECOMBINANT INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIGEN DETECTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CELL KILLING; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; ERADICATION THERAPY; GROWTH REGULATION; GROWTH STIMULATION; IMMUNE RESPONSE; IMMUNOTHERAPY; IN VIVO STUDY; MOUSE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; CYTOTOXICITY, IMMUNOLOGIC; FAS LIGAND PROTEIN; FEMALE; HUMANS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; NEOPLASMS, EXPERIMENTAL; NEUREGULIN-1; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0344081935     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-003-0410-y     Document Type: Article

References (30)

1. Becker JC, Pancook JD, Gillies SD, Furukawa K, Reisfeld RA (1996). T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 183:2361
2. Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA (1996). An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci USA 93:7826
3. Becker JC, Varki N, Gillies SD, Furukawa K, Reisfeld RA (1996). Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest 98:2801
4. Chen X, Levkowitz G, Tzahar E, Karunagaran D, Lavi S, Ben-Baruch N, Leitner O, Ratzkin BJ, Bacus SS, Yarden Y (1996). An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J Biol Chem 271:7620
5. Cordaro TA, de Visser KE, Tirion FH, Schumacher TN, Kruisbeek AM (2002). Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection? J Immunol 168:651
6. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM et al (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850
7. Esser MT, Dinglasan RD, Krishnamurthy B, Gullo CA, Graham MB, Braciale VL (1997). IL-2 induces Fas ligand/Fas (CD95L/CD95) cytotoxicity in CD8+ and CD4+ T lymphocyte clones. J Immunol 158:5612
8. Garza KM, Agersborg SS, Baker E, Tung KS (2000). Persistence of physiological self antigen is required for the regulation of self tolerance. J Immunol 164:3982
9. Geiger T, Gooding LR, Flavell RA (1992). T-cell responsiveness to an oncogenic peripheral protein spontaneous autoimmunity in transgenic mice. Proc Natl Acad Sci USA 89:2985
10. Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD, Allen PM (2000). Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 13:265
11. Ho WY, Yee C, Greenberg PD (2002). Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. J Clin Invest 110:1415
12. Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD et al (1992). Identification of heregulin, a specific activator of p185erbB2. Science 256:1205
13. Jodo S, Hohlbaum AM, Xiao S, Chan D, Strehlow D, Sherr DH, Marshak-Rothstein A, Ju ST (2000). CD95 (Fas) ligand-expressing vesicles display antibody-mediated, FcR-dependent enhancement of cytotoxicity. J Immunol 165:5487
14. Lo D, Freedman J, Hesse S, Palmiter RD, Brinster RL, Sherman LA (1992). Peripheral tolerance to an islet cell-specific hemagglutinin transgene affects both CD4+ and CD8+ T cells. Eur J Immunol 22:1013
15. Lollini PL, Nicoletti G, Landuzzi L, De Giovanni C, Rossi I, Di Carlo E, Musiani P, Muller WJ, Nanni P (1998). Down regulation of major histocompatibility complex class 1 expression in mammary carcinoma of HER-2/neu transgenic mice. Int J Cancer 77:937
16. Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C, Rosenberg K, Yang D, Tang C (1996). The significance of heregulin in breast cancer tumor progression and drug resistance. Breast Cancer Res Treat 38:57
17. Lurquin C, Van Pel A, Mariame B, De Plaen E, Szikora JP, Janssens C, Reddehase MJ, Lejeune J, Boon T (1989). Structure of the gene of tum-transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells: Cell 58:293
18. Lustgarten J, Marks J, Sherman LA (1999). Redirecting effector T cells through their IL-2 receptors. J Immunol 162:359
19. Mitchell MS, Darrah D Yeung D, Halpern S, Wallace A, Voland J, Jones V, Kan-Mitchell J (2002). Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol 20:1075
20. Mizoguchi H, O'Shea JJ, Longo DL, LoefflerCM, McVicar DW, Ochoa AC (1992). Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258:1795
21. Reisfeld RA, Gillies SD (1996). Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy. J Clin Lab Anal 10:160
22. Revillion F, Bonneterre J, Peyrat JP (1998). ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34:791
23. Rosenstein M, Yron I, Kaufmann Y, Rosenberg SA (1984). Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res 44:1946
24. Ross JS, Fletcher JA (1998). The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16:413
25. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177
26. Tzahar E, Levkowitz G, Karunagaran D, Yi L, Peles E, Lavi S, Chang D, Liu N, Yayon A, Wen D et al (1994). ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. J Biol Chem 269:25226
27. Valmori D, Levy F, Miconnet I, Zajac P, Spagnoli GC, Rimoldi D, Lienard D, Cerundolo V, Cerottini JC, Romero P (2000). Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J Immunol 164:1125
28. Van den Eynde BJ, Boon T (1997). Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res 27:81
29. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643
30. Xu F, Yu Y, Le XF, Boyer C, Mills GB, Bast RC Jr (1999). The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res 5:3653